Display Settings:

Format

Send to:

Choose Destination
    Clin Exp Rheumatol. 2007 Mar-Apr;25(2):318-28.

    B-cell: a logical target for treatment of rheumatoid arthritis.

    Source

    Laboratory of Immunology, Brest University Medical School Hospital, Brest, France. youinou@univ-brest.fr

    Abstract

    The interest for B-cells in rheumatoid arthritis (RA) is currently being revived. They are involved in the development and activation of lymphoid architecture by regulating dentritic cell and T-cell function through cytokine production. Receptor editing an revising are also essential in B-cells and aid in preventing autoimmunity. Abnormalities in the subset distribution and a default in any task assigned to the B-cells may favor autoimmunity. Beneficied responses to B-cell depletion in RA by anti-CD20 monoclonal antibody rituximab illustrate the importance of B-lymphocytes in the pathogenesis of this disease. A new avenue has thus been opened, whereby B-lymphocytes return as a significant contributor to autoimmune disorders.

    PMID:
    17543163
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Clinical and Experimental Rheumatology

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk